A protein inhibitor for human DNA ligase I has recently been identified. It was copurified with a fraction of the enzymes from HeLa cells through several steps of chromatography. The inhibitor was first identified by the absence of ligation activity of the associated enzyme, while it retained the ability to form the ligase-[32P]AMP adducts. The inhibitor was eluted as a single peak at -0.250.30 M NaCl from a Mono S column. It inhibited the ligation of both double-stranded and single-stranded breaks by purified DNA ligase I but not by T4 DNA ligase and DNA ligase II. Subsequent gel-fitration chromatography indicated that this inhibitor, with a molecular mass of55-75 kDa, could form a complex with DNA ligase I and inhibited the DNA ligation activity.
interaction of inhibitor with DNA ligase I is one of the mechanisms of inhibition. These data indicate that this protein inhibitor for DNA ligase I may play a specific role in regulating DNA ligation during replication, repair, or recombination.
DNA ligase is essential for DNA replication, repair, and recombination by joining single-and double-stranded DNA with formation of phosphodiester bonds (1) (2) (3) (4) (5) (6) . Eukaryotic DNA ligases react with ATP, forming covalent enzyme-AMP intermediates; then the enzymes transfer the AMP group to the 5' end of the DNA to complete the joining reaction (1, 2) . Thus, a ligase-AMP complex assay was developed that was based on the unique ability of DNA ligases to react with [a-32P]ATP covalently, forming a ligase-[32P]AMP complex that is sufficiently stable during SDS/polyacrylamide gel electrophoresis (SDS/PAGE) (1, 2, 4) . Multiple forms of DNA ligase have also been documented in mammalian cells (1) (2) (3) (7) (8) (9) (10) (11) (12) (13) (14) . DNA ligase I was implicated in DNA replication, while DNA ligase II was associated with DNA repair (1-3, 10, 14) . However, very little is known about the regulation of these isozymes except that earlier reports indicated that poly(ADP-ribose) polymerase (PADPRP) and histones may affect the ligation reaction nonspecifically (14) (15) (16) . During the course of DNA ligases purification from HeLa cells, we identified a protein inhibitor for DNA ligase I, which copurified with a fraction of the enzyme that could form ligase-
[32P]AMP adducts. To the best of our knowledge, a DNA ligase I inhibitor from human cells has not been reported previously.
MATERIALS AND METHODS
Human DNA ligases I and II were isolated from HeLa cells (Invitron, Berkeley, MO) as described (11) , with specific activities of 10,100 and 11,900 units/mg of protein, respectively. The ligase-AMP labeling assay indicated that DNA ligase I contained a 90-kDa and a 78-kDa polypeptide, while DNA ligase II contained a 67-kDa polypeptide; only DNA ligase II could utilize poly(rA)-p(dT)16 as a substrate. Phosphocellulose, DEAE-agarose (Bio-Gel), CM-agarose (BioGel), hydroxylapatite, and protein standards were purchased from Bio-Rad; heparin-Sepharose, Mono S HR 5/5 column, Superose 12 column, poly(dA), poly(rA), and (dT)16 were from Pharmacia LKB; DNA-cellulose was from Sigma; restriction enzyme Bgl II, phage T4 DNA ligase, and T4 kinase were from GIBCO-BRL; [a-32P]ATP (3000 Ci/mmol; 1 Ci = 37 GBq) and [y32PJATP (3000 Ci/mmol) were from ICN.
Other chemicals were from Sigma or Fisher.
DNA Ligase Assays. The assay mixture (50 ,ul) for ligation of single-strand DNA breaks contained 50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 10 mM dithiothreitol, 1.2 mM ATP, 30,000 cpm of poly(dA)4[32P]p(dT)16, and DNA ligase. After incubation at 25°C for 20 min, the sample was either analyzed with gel electrophoresis or treated with calf intestine phosphatase (CIP), acid-precipitated, and assayed for radioactivity as described (5) . The ligase-AMP adduct assay and plasmid DNA ligation assay were carried out as described (11) .
Purification of the Inhibitor for DNA Ligase I from Human Cells. All steps of the purification were carried out at 4°C. In brief, 20 g of HeLa cells were extracted with 100 ml of extraction buffer (0.8 M NaCl/50 mM Tris'HCI, pH 7.6/15% glycerol/l mM EDTA/10 mM 2-mercaptoethanol/10 pug of leupeptin per ml/0.5 mM phenylmethylsulfonyl fluoride), and the protein extraction and (NH4)2SO4 fractionations were performed as described (11) . The precipitate from (NH4)2SO4 solution at 30-70% saturation was dissolved in and dialyzed for 8 hr against buffer A (25 mM Tris HCl, pH 7.6/15% (vol/vol) glycerol/0.1 mM EDTA/10 mM dithiothreitol/0.1 M NaCl). The sample was then applied to a phosphocellulose column (8.5 x 2.5 cm) equilibrated with buffer A. The sample was washed with buffer A and eluted with buffer A containing 0.5 M NaCl. The eluate was diluted with buffer A without NaCl until the final NaCl concentration was 0.1 M. The sample was then loaded onto a DEAE-agarose column (6.0 x 2.5 cm) preequilibrated with buffer A, and the column was washed extensively with the same buffer. The flowthroughs and the washed fractions were then combined, adjusted to pH 6.5, and loaded onto a CM-agarose column (4.5 x 2.5 cm) equilibrated with buffer B (buffer A at pH 6.5). The sample was washed with buffer B and then eluted with a linear gradient of 0.1-0.45 M NaCl in 100 ml of buffer B. The fractions at -0.18 M NaCl were pooled, dialyzed against buffer C (10 mM potassium phosphate, pH 7.6/15% glycerol/10 mM dithiothreitol/0.3 M NaCI), and then loaded onto a hydroxylapatite column (10 x 2.0 cm). The sample was washed with buffer C and eluted with a linear gradient of 0.01-0.30 M potassium phosphate in 80 ml of buffer C. DNA ligase II was eluted in a high-salt fraction (0.26 M potassium Abbreviations: PADPRP, poly(ADP-ribose) polymerase; CIP, calf intestine phosphatase; E-alone, enzyme alone; E+I, enzyme with inhibitor. *To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. phosphate) and was separated from DNA ligase I. The fractions eluted at about 0.2 M potassium phosphate were pooled, concentrated with a Centriprep concentrator-30 (Amico), and dialyzed against buffer D (15 mM potassium phosphate/5 mM MgCl2/15% glycerol/10 mM dithiothreitol/50 mM NaCl, pH 7.6). The sample was then loaded onto a double-stranded DNA-cellulose column (5.0 x 1.0 cm) and washed with buffer D. The column was eluted with 15 ml of buffer D containing 0.5 M NaCl. The eluate was diluted with buffer D without NaCl to a final concentration of 0.15 M NaCl, and loaded onto a heparin-Sepharose column (3.5 x 1.0 cm) equilibrated with buffer D containing 0.15 M NaCl. The sample was washed with buffer D and eluted with a linear gradient of 0.15-0.8 M NaCl in 30 ml of buffer D. Fractions 9 and 10 containing the inhibitor (see Fig. 1 ) were pooled and dialyzed against buffer F (30 mM potassium phosphate, pH 6.8/15% glycerol/10 mM dithiothreitol/50 mM NaCl). The sample was applied to a Mono S HR 5/5 column, washed with 4.0 ml of buffer F, and eluted with a linear gradient of 0.05-0.5 M NaCl in 24 ml of buffer F; 0.3-ml fractions were collected. Fractions 44-50 containing the inhibitor (see Fig. 2) were pooled, dialyzed against 55% TGED (50 mM Tris1HCl, pH 7.6/50%o glycerol/0.2 mM EDTA/10 mM dithiothreitol), and stored at -20°C.
RESULTS
Partial Phrification of the Inhibitor for DNA Ligase I. Previous data (2, 7-9, 11-13) indicated that, in the size range of 67-130 kDa, the majority of [a-32PIATP-labeled polypeptides in cell extracts were DNA ligases. During the course of purification of DNA ligases, we have noticed that certain fractions were able to form ligase-AMP adducts but were unable to ligate linearized plasmids. This suggested that either an inhibitor was present or that the enzyme retained its AMP-binding property but lost the ligation activity. A typical run for the identification of the ligase inhibitor from the heparin-Sepharose column is shown in Fig. 1 . The putative enzyme in fractions 9 and 10 of Fig. 1A showed strong activity in forming ligase-AMP adducts but was unable to ligate the linearized DNA plasmids (lanes 9 and 10 in Fig. 1B ). In contrast, DNA ligase I in fractions 16 and 17 of Fig. 1A showed much less activity for ligase-AMP adducts than those from fractions 9 and 10 but with much higher activity for the plasmid ligation (fractions 16 and 17 in Fig. 1B) . Thus, the heparin-Sepharose chromatography could effectively sepa- rate the putative inhibitor (fractions 9 and 10) from contaminating DNases (fractions 6-7 and 12, respectively, in Fig.  1B ). These data also showed that the putative inhibitor was coeluted with a fraction of the DNA ligases throughout various chromatographic steps. The putative inhibitor (fractions 9 and 10) was then purified further with the Mono S column. It was eluted as a single peak at -0.27 M NaCl in the linear gradient (Fig. 2 , fractions 44-50), while DNA ligase was eluted at -0.32 M NaCl (data not shown).
The molecular mass for the inhibitor was estimated to be -55-75 kDa by gel filtration (Fig. 3) . It was determined from a plot of Kavg as a function of the logarithm of the molecular mass of the protein standards [Kavg, the partition coefficient, was calculated by the following equation: Kavg = (Ve -VO)/(Vt -VO), where Ve = elution volume; VO = void volume = 6.7 ml; and Vt = total bed volume = 23.0 ml]. Moreover, the inhibitor was identified as a protein by its sensitivity to heating at 52°C and to trypsin treatment and by its resistance to RNase A treatment (data not shown).
Enzyme Specficity. The effect of inhibitor on T4 DNA ligase and human DNA ligases I and II was then determined. In the gel assay (Fig. 4A) , DNA ligase I was inhibited by increasing amounts of the inhibitor (lanes 2-8), while DNA ligase II (lanes [9] [10] [11] [12] [13] [14] [15] and T4 DNA ligase (lanes. [16] [17] [18] [19] [20] [21] [22] were not affected. The ligated substrates of the remaining samples were also quantitated by treatment with CIP, followed by v1)tab (Fig. 4B) . Similar results of enzyme specificity were observed with a M13 mp19 DNA hybridized with two adjacent complementary oligomers (to provide a substrate with a single-strand break) and with linearized plasmid as the substrate (data not shown).
Formation of DNA Ligase I-Inhibitor Complex. To determine if the inhibitor may bind to DNA ligase I, DNA ligase I alone [enzyme alone (E-alone)] and DNA ligase I mixed with the inhibitor (E+I) were then separately chromatographed through a Superose 12 column (Fig. 5) . The activities for the formation of ligase-[32P]AMP adduct and for the ligation of poly(dA) [32P]p(dT)16 were assayed in fractions 14-32 for both samples simultaneously. The E-alone fraction (Fig. 5A ) showed that material with activity for ligase I-AMP formation was eluted as a single peak between fractions 23 and 25 (Kavg = 0.33). However, with the E+I fraction, a distinct difference in the chromatographic profile was observed ( activities for DNA ligation of the E-alone and E+I fractions are presented in Fig. SD . For E-alone, the activity for enzyme-AMP adduct formation in Fig. SA coincided with the activity for DNA ligation in Fig. 5D . In the E+I fraction, >95% of the initial activity for ligation of labeled DNA was inhibited when compared with the E-alone fraction. However, the residual DNA ligation activity also appeared as two peaks, which coincided with the ligase-AMP activity. Thus, the radioactivity (measuring the activity of the ligase-AMP complex of fractions [20] [21] [22] in the E+I fraction was calculated as -58% of the total unbound DNA ligase I (fractions [23] [24] [25] in the E-alone fraction (Fig. SC) , whereas the ligation activity of the enzyme-complex (fractions [20] [21] [22] in E+I was calculated as 1% of the total unbound DNA ligase I (fractions 23-25) in E-alone (Fig. SD) . The low DNA ligation activity in the first peak of ligase-AMP indicated that when the proteinligase I complex was formed, the activity for DNA ligation was greatly inhibited. On the other hand, the low DNA ligation activity in the fractions for free DNA ligase I (second peak of E+I) could be the consequence of spillover by the free inhibitor or the enzyme-inhibitor complex, or both. It is also possible that under the conditions of the ligase activity assay, the equilibrium of the enzyme and inhibitor may have shifted in favor of the formation of the enzyme-inhibitor complex, so that the inhibition increases compared to the activity of ligase-AMP adduct in the same peak.
Dissociation (Fig. 6B) . This Kayg was similar to that when the inhibitor was chromatographed alone (Kavg = 0.44) in Fig. 3 Since the cDNA for human DNA ligase I has been cloned (17) and the ligase-adenylate site has been identified (18) , the 90-kDa and 78-kDa polypeptides of human DNA ligase I reported by us may represent processed products of the larger 125-kDa protein, similar to the proteolytic 85-kDa of calf thymus DNA ligase I (7).
In view of the ample evidence of differential repair and replication in the genome, the inhibitor and other factors (19) (20) (21) may act to prohibit the random replicative ligation of DNA by DNA ligase I, while allowing DNA ligase II, the putative repair enzyme, to be active in certain regions of the genome during S phase. Altered DNA ligase I activities and error-prone ligation (22) (23) (24) (25) (26) in cells from patients with Bloom syndrome (BS), in acute lymphoblastic leukemia (27) , and in cells undergoing differentiation and development (3, 28) have been documented. Since expression of a wild-type DNA ligase I gene in BS cells was reported recently (29) , the inhibitor may play a role in the apparent altered DNA ligase activities observed in these cells. The further elucidation of the role of the inhibitor for DNA ligase I in human cells will have great ramifications for DNA replication, repair, and recombination and for gene therapy.
